Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAR444656 in moderate to severe hidradenitis suppurativa
NCT06028230Phase 2Terminated
- Sponsor
- Sanofi
- Start
- Sep 2023
- Primary completion
- Oct 2025
- Modality
- Bivalent/Multivalent Binders, PROTACs (E3 ligase recruitment)
- Countries
- 8
01
Overview
Phase 2, randomised, double-blind trial of SAR444656 in hidradenitis suppurativa (HS) (3 arms), sponsored by Sanofi. Primary endpoint: Percent change from baseline in total abscess and inflammatory nodule count at 16 weeks. Started Sep 2023; status: terminated.
02
Drugs
SAR444656
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on NCT06028230.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06028230.